cerezyme

Rumors are that Sanofi has proposed to buy Genzyme for $70 a share. But analysts believe the likes of Pfizer and the U.K. 's GlaxoSmithKline could be interested as well.

For Genzyme Corp (GENZ), this year seems to have been plagued with one piece of bad news after another. On Wednesday, the biotechnology company announced that it was dropping development of its experimental kidney disease drug after it failed to show significant improvement over the company's...

Pharmaceutical drugmaker Genzyme (GENZ), based in Cambridge, Massachusetts, specializes in creating drugs for rare diseases. It's a small market, but it's highly lucrative: the Orphan Drug Act gives the company tax credits and enhanced patent protection, virtually guaranteeing that its drugs become...